Navigation Links
Dyadic International Reports Third Quarter 2013 Financial Results
Date:11/14/2013

JUPITER, Fla., Nov. 14, 2013 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI) ("Dyadic" or "the Company"), a global leader in the commercial application of biotechnology for the discovery, development and production of enzymes and other proteins, today announced financial results for the quarter and nine months ended September 30, 2013.

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "Our third quarter revenue performance reflects growing demand for our proprietary enzymes, especially due to our success in the animal feed market.  We added new sales channels into the food market that we anticipate will enable us to improve margins and accelerate sales growth in the coming quarters.  Our marketing and new product development activities have never been higher.  We continue to broaden and deepen our relationships with several of our strategic partners, have initiated two new product development programs, and are preparing to launch new C1-based products for the pulp & paper and textile markets in the first half of 2014."

Operating HighlightsDuring the quarter, C1 licensees made significant progress.  Some developments include:

  • BASF.  Dyadic achieved the technical milestones defined in the research and licensing agreement, specifically relating to the technology transfer.  The completion of this milestone entitles Dyadic to the final milestone payment of $1,000,000, which will be recognized in the fourth quarter.
  • Abengoa.  Based on publicly available information, Dyadic expects Abengoa to begin production at its Hugoton, Kansas cellulosic ethanol plant in the first or second quarter of 2014, with volume production occurring by mid-2014.  Dyadic expects to receive royalty payments in conjunction with the operation of this facility in 2014.
  • Sanofi.  Dyadic scientists have successfully purified and delivered a target protein to Sanofi, and we are now finalizing the purification process for the second.  The Company believes that Sanofi has, or will soon begin the pre-clinical testing phase using the delivered protein.
  • In support of its new product development initiative announced in the second quarter, Dyadic is expanding its Netherlands research facility by 40%.  The expansion should be complete by the end of the fourth quarter.  To offset the additional cost, Dyadic is closing its Greensboro, NC laboratory and relocating the capabilities.  In addition, Dyadic took cost reduction actions in IT and with certain external service providers during the quarter.  The full financial impact of these cost reductions will be seen during fiscal year 2014. 

    During the quarter, Dyadic received the approval of its thirteenth patent issued in the U.S. and 54th patent worldwide.  The patent is related to methods of developing and producing a variety of fungal enzymes.  The patent addresses methods to use novel enzymes in a variety of processes, including washing of clothing, detergent processes, bio-refining, de-inking and bio-bleaching of paper and pulp, and treatment of waste streams.

    Financial Results for the Quarter Ended September 30, 2013 vs. September 30, 2012Total revenue for the third quarter increased to $3.5 million compared to $2.5 million for the third quarter last year.  The increase in total revenue as compared to the same period last year was driven by a 55% increase in product related revenue, which was offset by a $211,000 decrease in research and development revenue.

    Net product-related revenue for the third quarter increased to $3.2 million compared to $2.1 million for the third quarter last year.  The increase was attributable to newly added sales channels into the food market and continued growth in the recovering poultry market with our key animal feed customers.

    There was no license fee revenue recognized in the third quarter.  The remaining $1.0 million upfront fee for the technology license that was signed with BASF on May 6, 2013 was due upon completion of the technology transfer.  The transfer was completed on October 11, 2013 and the remaining revenue will be recognized in the fourth quarter.  The payment was received on November 5, 2013.

    Research and development revenue for the third quarter decreased 50% to $216,000 compared to $427,000 for the third quarter of 2012.  This decrease was due to the delay in the start of certain external research and development projects and the reallocation of research and development resources from externally funded projects to new product development initiatives.  Dyadic is now generating additional research and development revenue from the ongoing research funded by BASF.

    Gross profit for the third quarter increased 14% to $691,000 compared to $614,000 for the third quarter last year.  The increase was due primarily to increased product related revenue and the associated margins.  Gross margins as a percent of sales were negatively impacted by changes to the product mix and the decreased research and development revenue, which generally have higher margins. 

    Operating expenses for the third quarter increased 44% to $2.0 million compared to $1.4 million for the same period last year.  The increase was due primarily to increased costs associated with litigation against the Company's former outside legal counsel of approximately $514,000.  The increased litigation costs were anticipated and are expected to continue into 2014.

    On October 22, 2013, the arbitration proceedings brought by Mr. Emalfarb against the Company were dismissed. In consideration for the dismissal, the Company agreed to reimburse Mr. Emalfarb approximately $313,000 for past expenses incurred.  Such amount is included in other expense in the condensed consolidated statements of operations for the quarter and as a component of accrued expenses in the condensed consolidated balance sheet as of September 30, 2013.  In addition to this reimbursement, Mr. Emalfarb will be entitled to receive a percentage of the net proceeds, if any, received by the Company related to the professional liability lawsuit against the Company's former outside legal counsel.

    On August 8, 2012, the Company received $525,000 in settlement of certain of its claims against two defendants in the Company's professional liability lawsuit against its former outside legal counsel which is included in other income for the three month period ended September 30, 2012.

    Net loss for the third quarter was $1.7 million, or ($0.05) per basic and diluted share, compared to a net loss of $392,000, or ($0.01) per basic and diluted share for the third quarter last year.

    Financial Results for the Nine Months Ended September 30, 2013 vs. September 30, 2012Total revenue for the nine months increased $134,000 to $13.0 million compared to $12.9 million for the same period last year.  The increase was due to a 22% rise in product-related revenue, which was offset by an aggregate decrease of $1.2 million in license fee revenue and research and development revenue for the nine months. 

    Net product related revenue for the nine months increased to $7.1 million from $5.8 million for the same period a year ago.  The year-to-date growth of $1.3 million was due primarily to increased sales to existing customers as well as new customers in food and animal feed.

    License fee revenue for the nine months decreased to $5.0 million compared to $5.5 million for the same period last year. No license fees were recognized in Q3 of either 2012 or 2013, however the Company will recognize the remaining $1.0 million access fee from BASF in the fourth quarter of 2013.

    Research and development revenue for the nine months decreased 41% to $941,000 compared to $1.6 million for 2012.  The decrease was due to the delay in the start of certain external research and development projects and the reallocation of research and development resources from externally funded projects to new product development initiatives, which are internally funded, and to accelerate the continued enhancements and improvements to our C1 Platform Technology. 

    Gross profit for the nine months decreased to $6.4 million compared to $7.4 million for the same period a year ago.  The decrease came primarily from the lower license fee revenue and decreased research and development revenue and their related margins previously mentioned. The remaining $1.0 million in revenue from the BASF license agreement will be recognized in the fourth quarter of 2013.

    Total operating expenses for the nine months increased 20% to $5.4 million compared to $4.5 million for the same period a year ago.  The increase was due primarily to increased costs associated with litigation against the Company's former outside legal counsel of approximately $1.2 million, which was partially offset by the recovery of a doubtful account of $300,000 that was previously reserved as of December 31, 2012.  The increased litigation costs were anticipated and are expected to decrease upon completion of expert witness preparation.  The professional liability lawsuit is expected to continue into 2014.

    During the third quarter of 2013, the Company recognized a loss of $313,000 on settlement of litigation, which is described above. During the third quarter of 2012, the Company received $525,000 in settlement of claims against certain former outside legal counsel. 

    Net income for the nine months was $121,000, or $0.00 per basic and diluted share, compared to a net income of $2.8 million, or $0.09 per basic and $0.08 per diluted share, for the same period a year ago.

    Financial Position and Cash Flow AnalysisAt September 30, 2013, cash and cash equivalents were $8.5 million compared to $4.0 million at December 31, 2012.  During the nine months ended September 30, 2013, the Company generated approximately $4.5 million in cash and cash equivalents.  The Company used $496,000 for the same period in 2012.

    In July 2013, the Company received the final installment of $2.5 million due under the Abengoa license agreement announced in April 2012.  On November 5, 2013, the Company received $842,000 for partial payment of the remaining upfront fee due under the BASF license agreement.  The payment was due upon completion of the transfer of certain technology to BASF.  In addition to the $842,000 the Company expects to receive approximately $950,000 in cash in the fourth quarter from taxes being withheld by the German government relating to the BASF agreement.

    Total Convertible Subordinated Debt ("Debt") as of September 30, 2013 was $6.8 million.  In January 2013, the Debt decreased by $182,000 from $7.0 million as of December 31, 2012, due to the conversion of Debt to common stock.  On October 1, 2013, the Company extended the maturity dates of all of its outstanding debt to January 1, 2015.  The Company has a right to prepay $6.8 million of the debt any time after March 31, 2014, without penalty, with 30 days written notice.  The remaining $1.4 million Note Payable to Stockholder is non-convertible, and is not subject to the prepayment provision.

    Capital expenditures for the nine months ended September 30, 2013 were approximately $148,000 and cash generated from the exercise of warrants and stock options was $218,000 for the same period.

    2013 Full-year OutlookAs a result of the BASF license transaction, the expected continued growth in product related revenues and other strategic partnerships, Dyadic expects 2013 total revenues to increase versus 2012.  Because of the increased non-recurring litigation costs, the Company may break even or generate a small loss for the year.  Net of non-recurring litigation costs, the Company expects to be profitable for 2013.

    The financial information contained in this press release should be read in conjunction with the financial statements and related footnotes which have been posted on the OTC market website at http://www.otcmarkets.com/stock/DYAI/filings and on Dyadic's website at http://dyadic.com/investorinfo/financials/.

    Conference CallA conference call to discuss third quarter 2013 results is scheduled for 5:00 p.m. Eastern Time on Thursday, November 14, 2013.  The conference call may be accessed by dialing +1 (888) 713-3595 (from the United States or Canada) or +1 (913) 905-3226 (from other countries) five to ten minutes prior to start time and providing the confirmation code 9272553.  A replay of the conference call will also be available on the Dyadic website shortly after the live event.

    About DyadicDyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries.

    Dyadic trades on the OTC Pink tier of the OTC market. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC market website (www.otcmarkets.com/stock/DYAI/quote).

    Cautionary Statement for Forward-Looking StatementsCertain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

     DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Nine Months Ended September 30,  Three Months Ended September 30, 2013201220132012Revenue: (Unaudited)  (Unaudited)  (Unaudited)  (Unaudited) Product Related Revenue, Net

    $

    7,082,214

    $

    5,797,971

    $

    3,244,856

    $

    2,093,125License Fee Revenue5,000,0005,500,000--Research and Development Revenue940,8101,591,309215,562426,789Total Revenue13,023,02412,889,2803,460,4182,519,914Cost of Goods Sold:6,667,0925,535,1102,769,0901,906,071Gross Profit6,355,9327,354,170691,328613,843Expenses:General and Administrative3,968,7933,241,1281,563,054984,213Sales and Marketing 660,798561,747241,186202,929Research and Development 795,616671,823226,122207,404Foreign Currency Exchange Loss (Gain), Net(47,310)21,866(80,360)(39,713)Total Expenses5,377,8974,496,5641,950,0021,354,833Income (Loss) from Operations978,0352,857,606(1,258,674)(740,990)Other Income (Expense) Interest Income6,6473,8763,6311,122Interest Expense(512,892)(524,445)(173,251)(176,726)Gain (Loss) on Settlement of Litigation(313,143)525,000(313,143)525,000Total Other Income (Expense)(819,388)4,431(482,763)349,396Income (Loss) Before Provision for Income Taxes158,6472,862,037(1,741,437)(391,594)Provision for Income Taxes(38,000)(65,000)--Net Income (Loss)

    $

    120,647

    $

    2,797,037

    $

    (1,741,437)

    $

    (391,594)Net Income (Loss) per Common ShareBasic

    $

    0.00

    $

    0.09

    $

    (0.05)

    $

    (0.01)Diluted

    $

    0.00

    $

    0.08

    $

    (0.05)

    $

    (0.01)Weighted Average Common Shares Used in CalculatingNet Income (Loss) Per Share:Basic32,507,98031,708,06333,240,74531,651,657Diluted34,019,67033,937,59833,240,74531,651,657 DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETSSeptember 30,
    2013December 31,
    2012ASSETS(unaudited)Current Assets:Cash and Cash Equivalents$

    8,496,333$

    3,990,062Restricted Cash196,796192,355Accounts Receivable, Net1,888,3801,260,798License Fee Receivable791,2503,500,000Inventory, Net1,678,8612,765,187Prepaid Expenses and Other Current Assets183,465237,389Total Current Assets13,235,08511,945,791Fixed Assets, Net396,442393,860Intangible Assets, Net555,056525,224Other Assets128,91316,173$

    14,315,496$

    12,881,048LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts Payable$

    1,779,946$

    1,687,177Accrued Expenses785,613412,483Accrued Interest Payable171,7611,905Note Payable to Stockholder-1,424,941Deferred Research and Development Obligation314,788567,400Income Taxes Payable38,000-Total Current Liabilities3,090,1084,093,906Note Payable to Stockholder1,424,941-Convertible Subordinated Debt6,818,0007,000,00011,333,04911,093,906COMMITMENTS AND CONTINGENCIESStockholders' Equity:Preferred Stock, $.0001 Par Value:Authorized Shares – 5,000,000; None Issued and Outstanding--Common Stock, $.001 par value,Authorized Shares – 100,000,000; Issued and Outstanding R
    33,240,745 and 31,656,245, Respectively33,24031,656Additional Paid-in Capital80,829,16379,847,761Stock to be Issued91,672-Accumulated Deficit(77,971,628)(78,092,275)2,982,4471,787,142$

    14,315,496$

    12,881,048 DYADIC INTERNATIONAL, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Nine Months Ended September 30, 20132012 (Unaudited)  (Unaudited) Operating Activities Net Income 

    $

    120,647$

    2,797,037 Adjustments to Reconcile Net Income to Net Cash (Used in) Operating Activities:  Depreciation and Amortization of Fixed Assets 145,404156,148 Amortization of Intangible and Other Assets 38,18138,182 Increase (Decrease) in Allowance for Doubtful Accounts (315,567)65,345 Increase in Inventory Reserve 80,000161,000 Compensation Expense on Stock Option Grants 562,375956,102 Changes in Operating Assets and Liabilities:  Accounts Receivable (312,015)29,478 License Fee Receivable 2,708,750(5,500,000) Inventory 1,006,326186,120 Prepaid Expenses and Other Current Assets 53,924(18,585) Accounts Payable 92,769(396,457) Accrued Expenses 373,129(47,204) Accrued Interest Payable 169,8561,774 Income Taxes Payable 38,00065,000 Deferred Research and Development Obligation (252,612)714,181 Net Cash Provided By (Used In) Operating Activities 4,509,167(791,879) Investing Activities  Purchases of Fixed Assets (147,986)(9,266) Cost of Patents (68,013)(58,291) Restricted Cash(4,441)(1,377) Net Cash (Used In) Investing Activities (220,440)(68,934) Financing Activities  Proceeds from Warrant Exercises 159,044- Proceeds from Stock Option Exercises 58,50037,075 Net Cash Provided by Financing Activities 217,54437,075 Net Increase (Decrease) in Cash and Cash Equivalents 4,506,271(823,738) Cash and Cash Equivalents at Beginning of Period 3,990,0623,691,755 Cash and Cash Equivalents at End of Period 

    $

    8,496,333$

    2,868,017 Supplemental Cash Flow Information:  Cash Paid for Interest 

    $

    340,409$

    520,201 Non-Cash Item:  Conversion of Convertible Debt into Shares of Common Stock 

    $

    182,000$

    - Non-Cash Advances to Employees for Stock Option and Stock Warrant Exercises 

    $

    206,980$


    '/>"/>
    SOURCE Dyadic International, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved


    Related biology technology :

    1. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
    2. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
    3. Dyadic International To Release First Quarter 2012 Financial Results And Host Conference Call
    4. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
    5. Dyadic International to Announce Second Quarter 2012 Financial Results and Host Conference Call on Monday, August 13, 2012
    6. Dyadic Netherlands To Develop Baking Enzymes For EU-Funded Research Project
    7. Dyadic International Reports 2012 Third Quarter Financial Results
    8. 12th U.S. Patent Issued To Dyadic International
    9. Dyadic International Upgraded By OTC Markets To "Current Information" Tier
    10. Dyadic International To Announce Year-End 2012 Financial Results And Host Conference Call On Thursday, March 7, 2013
    11. Dyadic International To Present At World Biofuels Markets
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/10/2016)... NX Prenatal Inc., a US based ... for early warning of adverse pregnancy outcomes, announced ... by Dr. Thomas McElrath of Brigham ... Medicine,s (SMFM) annual meeting held in ... The presentation reported initial positive top-line results regarding ...
    (Date:2/10/2016)... -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company ... for the treatment of prostate, brain, lung, head and ... for the second quarter and six months of fiscal ... --> --> Revenue was $1.19 ... ended December 31, 2015, a 12% increase compared to ...
    (Date:2/10/2016)... ... 2016 , ... Benchmark Research, a fully-integrated network of ... principal investigators (PI) to the roles of Chief Medical Officer, Clinical Research and ... Chu, a Benchmark Research PI in the Austin office, will assume the role ...
    (Date:2/10/2016)... ... February 10, 2016 , ... SonaCare Medical, LLC ... support program, Sonalink™ remote monitoring. The inaugural launch of this new technology occurred ... connecting Dr. Samuel Peretsman to a HIFU technical expert at SonaCare Medical headquarters. ...
    Breaking Biology Technology:
    (Date:2/2/2016)... YORK , Feb. 2, 2016 /PRNewswire/ ... facilities are primarily focused on medical screening ... measure point-of-care parameters. Wearable devices that facilitate ... user,s freedom of movement are being bolstered ... for human biomedical signal acquisition coupled with ...
    (Date:2/2/2016)... YORK , Feb. 2, 2016 ... of that Rising Market Are you interested ... analysis forecasts revenues for checkpoint inhibitors. Visiongain,s report ... market, submarket, product and national level. Avoid ... discover what progress, opportunities and revenues those emerging ...
    (Date:2/2/2016)... Va. , Feb. 2, 2016   ... award from the U.S. Army Research Office and ... the range and sensitivity of the company,s ... Past Accounting Mission and, more generally, defense-related DNA ... DNA phenotyping capabilities (predicting appearance and ancestry from ...
    Breaking Biology News(10 mins):